A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
Condition: Healthy Interventions: Drug: QL0605; Drug: US Neulasta Sponsor: Qilu Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
Severe Bullous Drug Eruption and Filgrastim
Conditions: Rare Diseases; Toxic Epidermal Necrolyses Interventions: Drug: Filgrastim; Drug: Placebo Sponsor: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
Condition: Healthy Interventions: Drug: QL0605; Drug: US Neulasta Sponsor: Qilu Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
Severe Bullous Drug Eruption and Filgrastim
Conditions: Rare Diseases; Toxic Epidermal Necrolyses Interventions: Drug: Filgrastim; Drug: Placebo Sponsor: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
Condition: Healthy Interventions: Drug: QL0605; Drug: US Neulasta Sponsor: Qilu Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
Severe Bullous Drug Eruption and Filgrastim
Conditions: Rare Diseases; Toxic Epidermal Necrolyses Interventions: Drug: Filgrastim; Drug: Placebo Sponsor: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
Condition: Healthy Interventions: Drug: QL0605; Drug: US Neulasta Sponsor: Qilu Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
Severe Bullous Drug Eruption and Filgrastim
Conditions: Rare Diseases; Toxic Epidermal Necrolyses Interventions: Drug: Filgrastim; Drug: Placebo Sponsor: Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 3, 2020 Category: Research Source Type: clinical trials
“Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction”: study protocol for a randomized controlled trial
DiscussionThe REC-DUT-002 trial is the first to evaluate dutogliptin in combination with G-CSF in patients with STEMI. Results will lay the foundation for an appropriately powered cardiovascular outcome trial to test the efficacy of this combined pharmacological strategy.Trial registrationEudraCT no.: 2018-000916-75. Registered on 7 June 2018. IND number: 123717 (Source: Trials)
Source: Trials - August 25, 2020 Category: Research Source Type: clinical trials
Clinical Specimen Collection From Pompe Disease Patients
Condition: Pompe Disease Intervention: Drug: Filgrastim Sponsors: Serhat Gumrukcu, MD PhD; Frida Therapeutics LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 20, 2020 Category: Research Source Type: clinical trials
